Patient finance is not broken but the system around it is (Executive Summary)

Over the past decade, dental patient finance in the UK has grown from a niche product into a meaningful part of private dentistry.

• Annual originations have increased from ~£60m in 2017 to over £600m today

• The addressable market now exceeds £1bn, driven by:

  • the rise of Invisalign and cosmetic dentistry

  • increasing private treatment demand

  • pressure on NHS capacity

On the surface, this looks like a success story. It is not.

The paradox

Despite:

• strong patient demand

• widespread awareness

• clear economic benefits for practices

…adoption remains inconsistent, fragmented, and highly variable.

In some practices:

• 40–70% of specialist revenue is financed

In others:

• it remains below 5–10%

This is not a demand problem. It is a system problem.

What the industry got wrong

The industry has treated patient finance as: a lending product to be distributed

Instead of: a payment system that needs to convert reliably

As a result, the market has optimised for:

• underwriting

• lender relationships

• pricing negotiation

But failed to optimise for:

• patient experience

• practice workflows

• conversion at the point of care

The consequence

Finance exists in most practices. It is simply not used to its full potential.

The real barriers to adoption

Three structural frictions explain the gap between potential and reality:

1. Practice-led friction

Finance is not consistently offered.

• teams lack confidence

• processes are not standardised

• access is inconsistent

Even today:

• some patients are actively guided toward finance

• others are never told it exists

Adoption depends less on the product — and more on who is on shift.

2. Operational complexity

Finance is not integrated into the practice workflow.

It behaves as:

• an additional process

• not a payment method

This creates:

• longer application times

• staff involvement

• delayed payouts (often 2–4 weeks)

• manual reconciliation

Compared to cards, finance introduces friction at every step.

3. Misaligned incentives

Practices focus on:

• the cost of finance (e.g. 7–9%)

Instead of:

• the value of conversion

This leads to:

• underuse

• inconsistent positioning

• negotiation-driven decisions

A system optimised for cost minimisation will not maximise revenue.

A structurally misaligned market

The competitive structure reinforces these problems.

The market evolved in layers:

• brokers built distribution

• lenders provided capital

• practices executed the journey

No single player controls:

• the full patient experience

• underwriting inputs

• operational execution

The result

The party carrying the risk is not the party controlling the system.

This has led to:

• inconsistent pricing

• fragmented technology

• repeated lender withdrawals following loss events

• failed market entry by large players (Klarna, HSBC, BNP, Barclays, others)

Dentistry has proven difficult not because demand is weak — but because:

It is a highly variable, poorly standardised environment that requires deep integration to operate effectively

What has changed

Two structural shifts now reset the market.

1. Full regulatory exposure (from 2026)

Historically:

• 50–60% of loans were unregulated

• limited Section 75 exposure

• lower compliance burden

Now: All lending becomes regulated

This means:

• full FCA oversight

• full Section 75 exposure

• full complaint handling

Implication

Risk can no longer be avoided — it must be managed.

2. System capability has caught up

New capabilities now exist:

• mobile-first applications

• real-time decisioning

• PMS integration

• AI-driven communication and follow-up

These make it possible to:

• remove friction

• standardise processes

• increase conversion

But adoption is uneven.

The shift underway

The market is moving from:

Old model

• fragmented

• broker-led

• negotiation-driven

• operationally heavy

New model

Integrated, system-driven, conversion-focused

Where success depends on:

• controlling the full workflow

• integrating into practice systems

• optimising for conversion, not just approval

What this means for practices

The key question is no longer: “Should we offer finance?”

It is: “Does our system convert patients consistently?”

Practices that succeed will:

• standardise their offering

• introduce finance early

• integrate it into workflows

• actively manage conversion

• treat finance as a core part of operations

Those that do not:

• will continue to underutilise it

• and lose high-value treatment opportunities

What this means for the market

Growth will continue.

But sustainability will depend on:

• underwriting quality

• system integration

• operational execution

Not:

• price

• or distribution alone

Bottom line

Patient finance does not fail at the point of approval.

It fails in the system that surrounds it.

And under full regulatory exposure:

• systems that are fragmented, manual, and opaque

• will become increasingly difficult to operate

Final statement

The industry has spent 15 years making finance available.

The next phase is about making it work.

And that requires a fundamental shift:

• from offering a product

• to operating a system.